Amylyx Pharmaceuticals, Inc. (AMLX): Free Cash Flow
-$123.48M
Year ended 2025-12-31
-$126.72M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$123.48M | n/m | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | -$167.80M | n/m | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $10.68M | n/m | 2025-03-04, From 2023-01-01 |
| 2022-12-31 | -$182.40M | n/m | 2024-02-22, From 2022-01-01 |
| 2021-12-31 | -$75.15M | n/a | 2024-02-22, From 2021-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Amylyx Pharmaceuticals, Inc. (AMLX) | 2025-12-31 | -$123.48M | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $7.39B | +16.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $12.85B | -7.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $9.07B | -7.7% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.70B | -0.7% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $28.84M | +101.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $12.36B | -31.7% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | -$15.98M | n/m |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | -$27.91M | n/m |
Compare AMLX, ABT, BMY, PFE side by side · Screen every company in Pharmaceutical Preparations ↗